Citation Impact
Citing Papers
Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
2013
A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis
2021 StandoutScienceNobel
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
2015 StandoutScience
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
2007 StandoutNobel
Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients
2012
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
2017 StandoutNature
Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
2015
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
mRNA-based dendritic cell vaccines
2014
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
A view on drug resistance in cancer
2019 StandoutNature
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
The European Regulatory Environment of RNA-Based Vaccines
2016
mRNA-based therapeutics — developing a new class of drugs
2014 StandoutNobel
The biology and management of non-small cell lung cancer
2018 StandoutNature
Integrating liquid biopsies into the management of cancer
2017
Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity
2016
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells
2016
Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems
2017
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 Standout
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
The ReNAissanCe of mRNA-based cancer therapy
2014
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma
2016
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
mRNA transcript therapy
2014 StandoutNobel
Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives
2017
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
2015 StandoutNature
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
2016
Long Overall Survival After Dendritic Cell Vaccination in Metastatic Uveal Melanoma Patients
2014
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
2017 StandoutNobel
Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience
2015
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions
2017
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
2019
Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy
2014
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
2014
mRNA Cancer Vaccines
2016
The Unexpected Importance of the Primary Structure of the Hydrophobic Part of One-Component Ionizable Amphiphilic Janus Dendrimers in Targeted mRNA Delivery Activity
2022 StandoutNobel
Computational design of a synthetic PD-1 agonist
2021 StandoutNobel
Establishment of NOD-Pdcd1-/-mice as an efficient animal model of type I diabetes
2005 StandoutNobel
Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy
2023 StandoutNobel
2015
Targeted and Equally Distributed Delivery of mRNA to Organs with Pentaerythritol-Based One-Component Ionizable Amphiphilic Janus Dendrimers
2023 StandoutNobel
Managing Immune Checkpoint-Blocking Antibody Side Effects
2015
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model
2016 StandoutNobel
One-Component Multifunctional Sequence-Defined Ionizable Amphiphilic Janus Dendrimer Delivery Systems for mRNA
2021 StandoutNobel
Therapeutic Targeting of the Tumor Microenvironment
2021
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
2016
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
2008 StandoutNobel
A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes
2022 StandoutScienceNobel
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
2018 StandoutScience
RNA-Based Vaccines in Cancer Immunotherapy
2015
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells
2003 StandoutNobel
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV + tumors when combined with an E6/E7 peptide vaccine
2015 StandoutNobel
Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity
2014
Cancer Genome Landscapes
2013 StandoutScience
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine
2001 StandoutNobel
Modulation of Regulatory T Cell Function by Monocyte-Derived Dendritic Cells Matured through Electroporation with mRNA Encoding CD40 Ligand, Constitutively Active TLR4, and CD70
2013
Preclinical Evaluation of TriMix and Antigen mRNA-Based Antitumor Therapy
2012
Targeted Delivery of mRNA with One-Component Ionizable Amphiphilic Janus Dendrimers
2021 StandoutNobel
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors
2016
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
2016 StandoutNobel
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
From the RNA world to the clinic
2016 Science
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines
2023 StandoutNobel
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Therapeutic cancer vaccines
2015
Immune Checkpoint Blockade in Cancer Therapy
2015 Standout
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
2002 StandoutNobel
N‐Carboxyanhydride Polymerization of Glycopolypeptides That Activate Antigen‐Presenting Cells through Dectin‐1 and Dectin‐2
2018 StandoutNobel
Works of Sofie Wilgenhof being referenced
Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma
2016
Adoptive cellular therapies: the current landscape
2018
Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors
2016
Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases
2014
Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens
2012
Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula
2014
Overcoming HLA restriction in clinical trials
2012
Dendritic Cells Loaded With mRNA Encoding Full-length Tumor Antigens Prime CD4+ and CD8+ T Cells in Melanoma Patients
2012
Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient
2011
Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma
2013
Anti-CTLA-4 antibody-induced Guillain–Barré syndrome in a melanoma patient
2011
Single-Step Antigen Loading and Maturation of Dendritic Cells Through mRNA Electroporation of a Tumor-Associated Antigen and a TriMix of Costimulatory Molecules
2014
Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor
2012
Therapeutic Vaccination With an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced Melanoma
2011
A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients
2013
Phase II study of autologous mRNA electroporated dendritic cells (TriMixDC-MEL) in combination with ipilimumab in patients with pretreated advanced melanoma.
2014
Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor.
2012
Characterization of CD8+T-Cell Responses in the Peripheral Blood and Skin Injection Sites of Melanoma Patients Treated with mRNA Electroporated Autologous Dendritic Cells (TriMixDC-MEL)
2013
Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies
2012